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Summary Transforming growth factor beta-i (TGF-P1) has been proposed as a mediator of tumour growth
in a number of tumours and cell lines including prostate, and in a recent study was shown to be up-regulated
in the stroma of breast cancer tissue following treatment with the anti-oestrogen tamoxifen. Immunolocalisa-
tion ofthe intracellular form ofTGF-P1 confirmed that the source of the stromal TGF-Pf was the peritumoral
fibroblasts. We present here the results of a study in which five patients with hormonally unresponsive
prostatic carcinoma and seven patients responding to a luteinising hormone-releasing hormone analogue had
prostate biopsies taken before and during treatment. These were stained for TGF-P expression prior to
treatment and at either relapse or 3 months later respectively. Six of seven clinically responding tumours and
three of five relapsed tumours showed up-regulation of extracellular TGF-p1, again primarily in the stroma,
with no apparent up-regulation of intracellular TGF-p1, TGF-P2 or TGF-P3. These data illustrate that the
epithelial growth inhibitor TGF-P1 can be induced by hormonal manipulation in prostate cancer in vivo, and
may continue to be up-regulated even after relapse. This suggests that relapse of hormonally treated prostate
cancer may be associated with a failure of the epithelium to respond to stromal TGF-p1.
Carcinoma of the prostate is now the most commonly diag-
nosed male cancer in the USA, with an annual incidence of
86,000 cases in 1990. In the UK the reported incidence is
lower, with 19.5 cases per 100,000 males reported in 1986; in
both countries it is now the second most common cause of
male cancer death and the incidence appears to be increasing.
The disease tends to present at an advanced stage
unsuitable for radical treatment (Whitmore, 1984). Because
some 80-90% of tumours are initially sensitive to androgen
deprivation, hormonal manipulation, either alone or as an
adjuvant therapy, is used in a large number of patients with
an average response time of around 15 months. However,
following relapse there is no universally effective form of
treatment and the prognosis is extremely poor (Fossa et al.,
1992). There is no reliable method at present of predicting
which tumours will not respond to treatment, and conven-
tional assessment of the androgen receptor content of tumour
cells does not seem to be of significant help. The mechanism
of regression of prostate cancer in response to androgen
deprivation is probably via a pathway of programmed cell
death, as this has been demonstrated both in the rat ventral
prostate following castration (Kyprianou & Isaacs, 1988) and
in androgen-dependent LNCaP prostate cancer cells, which
undergo programmed cell death in the absence of exogenous
androgens (Colletta & Kealey, 1991).
Until recently the synthetic oestrogen diethylstilboestrol
was a common method of medical treatment of prostate
cancer, although it has fallen from favour because of its
unacceptable levels of cardiovascular side-effects (Henrikson
& Edhag, 1986). The majority of British urologists now use
either orchiectomy or luteinising hormone-releasing hormone
analogues (LHRH) in this context. Both stilboestrol (Schultz
& Bauer, 1988) and LHRH analogues (Qayum et al., 1990;
Limonta et al., 1992) are known to have directly cytotoxic
effects on prostatic cancer cells in vitro, but the conventional
view of their mode of action centres around suppression of
androgen production via the hypothalamic-pituitary- gona-
dal axis.
The role of stromal-epithelial interactions in the develop-
ing prostate has been elegantly demonstrated by Cunha and
co-workers (for example Cunha, 1990). These studies illus-
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trated that androgen receptors in the developing prostate
could be detected in the mesenchyme prior to their expres-
sion in the epithelial component of the gland. Further
experiments suggested that the hormonal responsiveness of
the epithelial cells in tissue recombinants was conferred by
soluble factors derived from, and specific to, different types
ofmesenchyme. The development ofmale sex organs appears
therefore to depend intimately on interaction between the
glandular and stromal elements in the developing embryo.
Proliferation of glandular tissue in the mature prostate
appears to be regulated by the stromal component, implying
that paracrine regulation of prostatic epithelial cells by the
stroma persists throughout life. In addition, prostatic stromal
cells are capable of inhibiting epithelial prostatic cancer cells
in culture, which would appear to be an organ-specific
finding in view of the fact that skin fibroblasts in such a
system cause a stimulation of cell growth (Kooistra et al.,
1991).
TGF-P1I is a member of a family oftissue polypeptides that
play a number of roles in the development, differentiation
and growth of epithelial tissues. In most breast cancer cell
types in vitro the TGF-ps are potent inhibitors of cellular
proliferation (Knabbe et al., 1987), and this has been found
to be the case in human PC-3 (Goldstein et al., 1991) and
LNCaP cells (Schuurmans et al., 1991) as well as Dunning
rat prostate cancer cells in vitro (Steiner & Barrack, 1992). In
oncogene-induced mouse prostate carcinoma and mesen-
chymal dysplasia, elevated levels ofTGF-,11 are found, which
led Mertz et al. (1991) to postulate that this might be due to
a mesenchymal stimulation of the epithelium towards malig-
nant change. Steiner & Barrack (1992) have also reported
that clones of Dunning rat prostate cancer cells that overex-
press TGF-P1 form more anaplastic and larger tumours; thus
there would initially appear to be some possible conflict as to
whether TGF-P1 does possess an inhibitory effect in vivo.
Further experiments by Kyprianou and colleagues (for exam-
ple Kyprianou & Isaacs, 1989) have gone a considerable way
towards showing that a negative inhibitory paracrine path-
way exists, by demonstrating the presence of TGF-P recep-
tors in the rat ventral prostate, which is negatively regulated
by androgens and which corresponds to a rise in TGF-P
production during castration-induced programmed cell death.
They have also shown that TGF-13 can inhibit rat prostate
cells in vivo, even with physiological levels of androgens
present (Martikainen et al., 1990).
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The present study was carried out to determine whether
TGF-P1 synthesis and secretion might be induced in human
prostate cancer after androgen ablation. By comparing the
immunohistochemical appearance of matched biopsies taken
before and after treatment, we are able to demonstrate a
significant induction of the extracellular form of TGF-pl,
with only minimal induction of the intracellular form of
TGF-P1 and no obvious change in the expression of TGF-P2
or TGF-P3.
Materials and methods
In the first group of prostate cancer specimens, which were
used partly to verify the applicability of the antibodies to
prostate tissue, all patients had metastatic disease at initial
diagnosis. The second biopsy was obtained from transureth-
ral resection of outflow obstruction. All these patients had
evidence of progressive disease at the time of their second
biopsy as shown by increase in either prostate-specific
antigen (PSA) or prostatic acid phosphatase, plus the
appearance of new metastases on bone scans. The average
duration from treatment to second biopsy in these patients
was 18.8 months (range 14.5-27.0 months). Four of these
patients had been treated by orchiectomy and one with
diethylstilboestrol.
In the second group of responding patients, eight patients
with histologically diagnosed carcinoma of the prostate were
assessed as being suitable for inclusion in a trial of hormonal
cytoreduction prior to radical radiotherapy (Shearer et al.,
1992). In this study LHRH agonist therapy (leuprorelin
acetate, Lederle, 3.75 mg depot injection every 4 weeks) was
given until stabilisation of prostate volume was observed by
monthly volume measurements. When the volume was stable
external beam radiotherapy was given and the medication
was discontinued at the completion of radiotherapy.
In addition to the initial diagnostic biopsy these patients
had a second biopsy between 3 and 4 months from the start
of treatment (average 13.4 weeks, range 12-17 weeks), prior
to radiotherapy. All patients were known to have normal sex
hormone profiles prior to commencing treatment. This study
was approved by the local ethical committee.
Conventional histological sections were also obtained from
these second biopsies, which were obtained via the transrectal
route under ultrasound guidance. In one case (patient 3) the
second biopsy was in the form of a transurethral resection, as
the patient had developed acute retention following his initial
biopsy and failed a trial without catheter during treatment,
necessitating surgical correction of his outflow obstruction.
One patient whose second biopsy showed no evidence of
tumour was excluded from evaluation. All these patients
showed an objective clinical response to treatment as defined
by a fall in both PSA levels and prostatic volume as
measured by a multiplanimetric method using a 7-MHz Bruel
and Kjaer transrectal ultrasound probe, correlating well with
previous results using this regimen (Shearer et al., 1992).
All biopsy specimens for histological examination were
fixed in formalin prior to paraffin embedding and sectioning
at 4 [m. Sections were then placed on gelatin-coated slides.
For the immunohistochemical analysis, polyclonal antibodies
to the different TGF-P isoforms were raised in rabbits using
synethic peptides as immunogens and purified as previously
described (Flanders et al., 1989). Two different antibodies
were used for TGF-p1; TGF-P1-LC, which recognises the
intracellular form of TGF-p1, and TGF-P1-CC, which recog-
nises the extracellular form of the peptide. The specificity of
these antibodies for the intracellular and extracellular forms
of TGF-PJI has previously been demonstrated in a number of
studies (Flanders et al., 1989; Butta et al., 1992).
These antisera are specific for the different TGF-P
isoforms, and immunohistochemical staining is blocked by
preincubation with the immunising peptides. The immunohis-
tochemical techniques used may recognise latent as well as
active TGF-P as the process of fixing the tumour specimens
activates any latent TGF-,B. Each matched pair of specimens
was stained side by side for the TGF-P isoforms to allow
direct comparison of the sections and to reduce the pos-
sibility of experimental variation. The duration of exposure
to the antibody was 16 h at room temperature in a
humidified staining chamber with the antibodies used at a
final concentration of 10gml-'. Bound antibodies were
localised with the use of a biotinylated goat anti-rabbit IgG
and peroxidase-labelled avidin-biotin complexes obtained
from Vector Laboratories. The sections were then stained
with 3-3'-diaminobenzidine and counterstained with Mayer's
haematoxylin.
Control slides were stained with normal rabbit IgG at
lO gml-'. Following staining the sections were reviewed
without access to their origin or relationship to one another,
and assigned scores relating to the degree of immunoreac-
tivity within and immediately adjacent to the carcinoma.
Scores were assigned as follows: +, little or no staining; +,
slight or sporadic staining; + +, intense localised staining:
+ + +, very intense widespread staining. It was noted that
there was considerable perineural staining in most specimens;
this was not included in the scoring unless there was also
obvious perineural tumour invasion.
Results
In the relapsed group of five patients (patients numbers 1-5
in Table I), three of the patients showed an up-regulation of
anti-TGF-P-CC-immunoreactive TGF-B1 expression, mainly
in the extracellular component of the stroma. The extent of
intracellular staining for TGF-P1 with the LC antibody
showed no obvious differences in the intracellular peptide
before or after treatment. There were no differences in the
staining for TGF-P2 or TGF-P3, both of which exhibited
very faint staining levels (data not shown). No obvious fac-
tors could be seen to account for the lack of the induction of
extracellular TGF-P1 in patients 2 and 4, both of whom had
been orchiectomised. The most dramatic up-regulation of
extracellular TGF-P1 in this group of relapsed patients was
in a patient treated by orchiectomy (patient number 1 in
Table I, and Figure la and b). There was also an up-
regulation of extracellular TGF-PI1 in the single patient
treated with diethylstilboestrol (Figure Ic and d).
In the responiding patients (patient numbers 6-12 in Table
I) the pattern was essentially identical with a widespread
induction of extracellular TGF-P1 expression after LHRH
agonist treatment (see Figure le and f) with no discernible
changes in the levels of pre- and post-treatment intracellular
TGF-P1, TGF-P2 or TGF-P3 (data not shown for TGF-132
Table I Summary of staining for the extracellular (CC) and
intracellular (LC) forms of TGF-P1 in patient samples pre- and
post-androgen ablation. Slides were assessed by three independent
investigators and assigned staining intensities as described in
Materials and methods
Treatment and TGF-PI-CC TGF-PI-LC
patient Before After Before After
Orchiectomy
1 + +++ + +
2 - _ + -
3 - ++ _ _
4 + - _ _
Stilboestrol
5 + ++ + +
LR-RH
agonists
6 - ++ + +
7 + ++ + +
8 + +++ + +
9 + + + +
10 + ++ + +
11 + ++ + +
12 + +++ + +132 G.H. MUIR et al.
a
f
Figure 1 a, Prostate cancer sample pre-orchiectomy; b, prostate cancer sample post-orchiectomy; c, prostate cancer sample
pre-diethylstilboestrol treatment; d, prostate cancer sample post-diethylstilboestrol treatment; e, prosta'te cancer sample pre-LHRH
agonist treatment; f, prostate cancer sample post-LHRH agonist treatment. All six samples were stained with the anti-CC antibody
to extracellular TGF-131. The pre- and post-treatment sections were from the same patient and were stained side by side at the same
time. g, Peritumoral fibroblasts post-orchiectomy stained with the anti-LC antibody to intracellular TGF-131. All
magnifications x 100.
and -P3). Again no immediate differences could be found
between the one patient who did not show extracellular
TGF-P1 induction (patient number 4 in Table I) and the
other patients, who all showed some degree of extracellular
TGF-P1 up-regulation after LHRH agonist treatment.
In all the patient samples demonstrating an induction of
extracellular TGF-P1 the staining was principally seen
around and between the stromal fibroblasts adjacent to the
tumour. Very little staining for either intracellular or extra-
cellular TGF-,B1 was seen in or between the epithelial cells
themselves, suggesting the tumour stromal fibroblasts as the
probable site of origin,of the stromal TGF-p1. In addition,
substantial intracellular TGF-PI could be seen in the
peritumoral fibroblasts using the anti-TGF-,Bl-LC antibodyTGF-4 IN PROSTATE CANCER 133
(see Figure Ig). TGF-132 and TGF-P3 showed only very weak
or no immunoreactivity, which was mainly confined to the
epithelial cells and which was not influenced by androgen
ablative treatment (data not shown).
Discussion
This study confirms that extracellular TGF-P1 can be
induced in vivo by androgen ablation treatment of prostate
cancer, and that there appears to be a role for the phar-
macological manipulation of stromal-epithelial interactions
in vivo in human prostate cancer. The observation that
several of the patients whose specimens showed a response
were not receiving drug therapy but had been surgically
castrated suggests that this effect is unlikely to be due to a
direct cytotoxic drug effect, but may be the result of a
paracrine pathway induced by androgen withdrawal. If this is
indeed the case it might explain why the androgen receptor
content within the epithelial component of the tumour does
not necessarily correlate with response to treatment, as such
a response may well be initiated by the mesenchymally
derived stromal fibroblasts.
The fact that three of the relaped tumours continued to
exhibit increased levels of TGF-PI while no longer respon-
ding to hormone withdrawal may indicate that, despite the
paracrine growth inhibition from the stromally derived TGF-
P1, these tumours had developed alternative pathways of
growth stimulation. Alternatively, this could be explained by
the emergence of a population of tumour cells which had
ceased to respond to the growth-inhibitory effects of TGF-P,
either by loss of the TGF-,11 receptor or by some post-
receptor defect leading to a failure of the TGF-P1 signal
transduction pathway. Androgen receptor immunolocalisa-
tion was not carried out in this study, and it might be
interesting to examine whether there were any differences in
androgen receptor content between those cases which showed
up-regulation of extracellular TGF-,1I and those which did
not. Because of the diversity of the strategies used here to
lower circulating androgen levels it seems unlikely that any of
these have a de novo effect on TGF-01 production. What
seems more plausible is that physiological concentrations of
androgens negatively regulate TGF-1I expression at either
the transcriptional or post-transcriptional level and that an-
drogen ablation treatment acts by relieving this negative
regulation, allowing the TGF-P1 to be expressed and to elicit
its typical growth-inhibitory profile. Regulation at the trans-
lational level is most likely with examples of steroids and
their antagonists, as well as retinoids, regulating TGF-1 pro-
duction in a post-transcriptional fashion (Knabbe et al.,
1987; Glick et al., 1989; Colletta et al., 1991) by a mechanism
thought to involve stem-loop structure in the 5'-untranslated
region of TGF-P1 mRNA (Kim et al., 1992). The present
data are also consistent with the finding that androgen-
induced epithelial proliferation in the mature prostate is
mediated by androgen receptors present in the stromal
fibroblasts (Cunha & Donjacour, 1987), and further supports
our studies in breast cancer suggesting that some hormonal
influences on epithelium may originate from the paracrine
effects of the adjacent mesenchyme (Butta et al., 1992).
These data are suggestive of a window of opportunity in
the possible chemoprevention of human prostate cancer.
Various studies have shown that in the early stages of
premalignant and malignant change many epithelia retain
their sensitivity to TGF-P (Wakefield & Sporn, 1990) so that
any inducer ofTGF-P expression might offer some hope as a
chemopreventative agent. Glick et al. (1989) have previously
shown that synthetic retinoids are capable of inducing TGF-
P2 expression from a wide variety ofepithelia in the rat, so it
may be possible to synergystically combine retinoids with
androgen ablation in elderly men to successfully chemopre-
vent prostate cancer.
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